Remove Networking Remove Patients Remove Pharma Remove Pharmaceutical manufacturing
article thumbnail

How one pharma “family business” places patients first

pharmaphorum

When people think about pharma, they often think about “big” pharma: large, faceless corporations. And just as a family business thrives on its connection to the community, Chiesi is committed to connecting to the global patient community. Caring for a global community.

article thumbnail

Leading pharmaceutical logistics and pharma supply chain companies

Pharmaceutical Technology

The pharmaceutical supply chain is a global and complex network that includes a wide range of stakeholders such as pharmaceutical manufacturers, wholesale distributors, and pharmacy benefit managers (PBM), to ensure efficient and timely delivery of medications to the patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Kerry, Ireland.

article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

Recommendations were also published earlier this year for all stakeholders in the pharma supply chain. In this Q&A EPR speaks to Naser Al Yammahi the Deputy CEO of Hayat Biotech about pharmaceutical supply chain challenges and how they can be addressed. Globalisation and supply chain complexity are a factor.

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

By enrolling participants with a wide range of baseline characteristics, study populations will more accurately reflect the patients likely to take the drug if it is approved. Cancer patients treated in clinical trials live substantially longer than those not treated in trials and benefit from lower hospital readmissions. 2] Figure 1.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. But it is not a simple answer. Furthermore, it is estimated to reach $6.5

article thumbnail

The Pandemic Treaty and the opportunity to end ‘vaccine apartheid’

pharmaphorum

Of significant interest to the pharma industry are the suggestions in the draft text that money granted for research on infectious diseases could include specifications on how eventual products could be marketed.